Immuneering Corp Stock Performance
| IMRX Stock | USD 5.00 0.25 4.76% |
The company retains a Market Volatility (i.e., Beta) of -0.0773, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Immuneering Corp are expected to decrease at a much lower rate. During the bear market, Immuneering Corp is likely to outperform the market. At this point, Immuneering Corp has a negative expected return of -0.34%. Please make sure to check out Immuneering Corp's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immuneering Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Immuneering Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.76) | Five Day Return 2.25 | Year To Date Return (24.47) | Ten Year Return (71.57) | All Time Return (71.57) |
1 | Wall Street Analysts See a 126.21 percent Upside in Immuneering Can the Stock Really Move This High | 11/26/2025 |
2 | All You Need to Know About Immuneering Rating Upgrade to Buy | 12/29/2025 |
3 | Acquisition by Feinberg Peter of 7888 shares of Immuneering Corp at 6.58 subject to Rule 16b-3 | 12/31/2025 |
4 | Immuneering Announces Exceptional 64 percent Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib mGnP | 01/07/2026 |
5 | Assessing Immuneering Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress | 01/09/2026 |
6 | Acquisition by Feinberg Peter of 20000 shares of Immuneering Corp at 4.3452 subject to Rule 16b-3 | 01/12/2026 |
7 | Acquisition by Leah Neufeld of 2626 shares of Immuneering Corp at 4.153 subject to Rule 16b-3 | 01/13/2026 |
8 | Acquisition by Brett Hall of 2298 shares of Immuneering Corp at 4.57 subject to Rule 16b-3 | 01/15/2026 |
9 | Immuneering Director Acquires 1.8 percent More Stock | 01/16/2026 |
10 | Immuneering Insider Harold Eugene Brakewood Purchases 5,250 Shares | 01/21/2026 |
11 | Acquisition by Morales Mallory of 23850 shares of Immuneering Corp at 3.01 subject to Rule 16b-3 | 01/28/2026 |
12 | Acquisition by Zeskind Benjamin J. of 688000 shares of Immuneering Corp at 4.91 subject to Rule 16b-3 | 02/03/2026 |
13 | Acquisition by Bookman Michael of 1020 shares of Immuneering Corp at 6.8299 subject to Rule 16b-3 | 02/04/2026 |
14 | Acquisition by Berman Ann E of 33350 shares of Immuneering Corp at 1.9 subject to Rule 16b-3 | 02/09/2026 |
15 | Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | 02/18/2026 |
| Begin Period Cash Flow | 59.4 M | |
| Total Cashflows From Investing Activities | 26.4 M |
Immuneering | Build AI portfolio with Immuneering Stock |
Immuneering Corp Relative Risk vs. Return Landscape
If you would invest 749.00 in Immuneering Corp on November 23, 2025 and sell it today you would lose (249.00) from holding Immuneering Corp or give up 33.24% of portfolio value over 90 days. Immuneering Corp is currently does not generate positive expected returns and assumes 7.5013% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Immuneering, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immuneering Corp Target Price Odds to finish over Current Price
The tendency of Immuneering Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.00 | 90 days | 5.00 | about 79.26 |
Based on a normal probability distribution, the odds of Immuneering Corp to move above the current price in 90 days from now is about 79.26 (This Immuneering Corp probability density function shows the probability of Immuneering Stock to fall within a particular range of prices over 90 days) .
Immuneering Corp Price Density |
| Price |
Predictive Modules for Immuneering Corp
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immuneering Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Immuneering Corp Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immuneering Corp is not an exception. The market had few large corrections towards the Immuneering Corp's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immuneering Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immuneering Corp within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | -0.08 | |
σ | Overall volatility | 1.03 | |
Ir | Information ratio | -0.02 |
Immuneering Corp Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immuneering Corp for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immuneering Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immuneering Corp generated a negative expected return over the last 90 days | |
| Immuneering Corp has high historical volatility and very poor performance | |
| Net Loss for the year was (61.04 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85. | |
| Immuneering Corp has a poor financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
Immuneering Corp Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immuneering Stock often depends not only on the future outlook of the current and potential Immuneering Corp's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immuneering Corp's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 30 M | |
| Cash And Short Term Investments | 36.1 M |
Immuneering Corp Fundamentals Growth
Immuneering Stock prices reflect investors' perceptions of the future prospects and financial health of Immuneering Corp, and Immuneering Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immuneering Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 94.68 M | ||||
| Shares Outstanding | 64.57 M | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 563.62 X | ||||
| Gross Profit | 158.83 K | ||||
| EBITDA | (63.69 M) | ||||
| Net Income | (61.04 M) | ||||
| Cash And Equivalents | 128.1 M | ||||
| Cash Per Share | 4.85 X | ||||
| Total Debt | 4.16 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 33.99 X | ||||
| Book Value Per Share | 3.59 X | ||||
| Cash Flow From Operations | (55 M) | ||||
| Earnings Per Share | (1.79) X | ||||
| Market Capitalization | 322.85 M | ||||
| Total Asset | 52.71 M | ||||
| Retained Earnings | (224.3 M) | ||||
| Working Capital | 32.08 M | ||||
About Immuneering Corp Performance
Evaluating Immuneering Corp's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immuneering Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immuneering Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.54) | (1.46) | |
| Return On Capital Employed | (1.63) | (1.55) | |
| Return On Assets | (1.33) | (1.26) | |
| Return On Equity | (1.70) | (1.61) |
Things to note about Immuneering Corp performance evaluation
Checking the ongoing alerts about Immuneering Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immuneering Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immuneering Corp generated a negative expected return over the last 90 days | |
| Immuneering Corp has high historical volatility and very poor performance | |
| Net Loss for the year was (61.04 M) with profit before overhead, payroll, taxes, and interest of 158.83 K. | |
| Immuneering Corp currently holds about 128.1 M in cash with (55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.85. | |
| Immuneering Corp has a poor financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
- Analyzing Immuneering Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immuneering Corp's stock is overvalued or undervalued compared to its peers.
- Examining Immuneering Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immuneering Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immuneering Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immuneering Corp's stock. These opinions can provide insight into Immuneering Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.